Learning Center
News and Events
Click here for the latest technological updates and other breaking news in the world of refractive surgery. We will also list TV and radio appearances, special presentations and events involving Hale Vision.
3/25/2006
Dr. Hale was invited to lecture on the advanced technologies of the new Visx Star S4 IR system at
the Spring meeting of the American Society of Cataract & Refractive Surgery in San Francisco on
March 19th, 2006.
(
read more)
Return to top
3/10/2006
ESPN Radio Milwaukee morning host Bill Johnson had Lasik at Hale Vision on Wednesday March 8,
2006. Bill had IntraLasik, utilizing the Intralase to make a blade-free flap and CustomVue
reshaping using the Visx Star S4 IR, Iris Registration system.
(
read more)
Return to top
11/1/2005
It’s official! On December 8th, 2005 at the Humphrey Scottish Rite Center in
downtown Milwaukee, there will be a benefit concert starring Daryl Stuermer, lead
guitarist for Phil Collins and Genesis. This concert will be on behalf of Gilda’s
Club of Southeastern Wisconsin, whose mission is to support those living with all
forms cancer and their friends and relatives through education and consultation.
(
read more)
Return to top
10/26/2005
Hale Vision Receives Intralase FS High Speed Upgrade
On October 26th, 2005 Hale Vision was proud to receive the first high–speed upgrade
in Southeastern Wisconsin for our Intralase FS system. This upgrade doubles the speed
of our laser from 15,000 pulses/sec to an astonishing 30,000 pulses/sec and allows
for greater patient comfort and increased precision.
Return to top
9/2/2005
The word is filtering onto the street that Visx has received verbal approval of
CustomVue treatments for high myopia with astigmatism. The ranges are probably
about what we hoped for, -11.00 Diopters of nearsightedness with up to 3 Diopters
of astigmatism. This was the final piece of the puzzle that we were waiting for at
Hale Vision. Now we can complete are All-Laser, All-Custom Lasik program. Look for
exact information as it is published.
(
read more)
Return to top
8/19/2005
On August 19, 2005, Dr. Hale became the first refractive surgeon in Wisconsin to install and use the
new Visx Star S4 IR system. IR or Iris Registration is the latest step in CustomVue technology
pioneered by Visx. The idea is to ensure the best alignment of the laser treatment pattern possible.
(
read more)
Return to top
8/16/2005
San Diego, CA - An independent researcher reporting at the annual meeting of the American Society of
Cataract and Refractive Surgery (ASCRS) finds that “Custom” or Wavefront-guided LASIK
produces superior vision quality compared to traditional LASIK eye surgery.
(
read more)
Return to top
7/8/2005
We are proud to announce the launch of the new Hale Vision Blog. This sister site will provide a forum
for Dr. Hale to provide up to the minute commentary on developments in the laser and implant vision
correction fields, and to dialog with site visitors, who are invited to post any questions or comments.
Return to top
6/11/2005
This in-depth article covers the new options in surgical vision correction, including implants. Read the article,
then learn more about implants from our
online guide.
Return to top
4/7/2005
Joanie Meyers of “Lynch & Meyers” has custom IntraLASIK at Hale Vision
Joanie Meyers, co-host of Lynch & Meyers, one of Milwaukee’s most popular morning radio talk shows
(Fm 97.3, the Brew), had surgery at the Hale Vision Laser & Implant Center. Joanie had Custom IntraLASIK
with the “bladeless” Lasik technique.
Return to top
3/28/2005
FDA approves of the ReZoom Multifocal Refractive Lens
Advanced Medical Optics Adds to Its Market-Leading Portfolio of Refractive IOL’s With FDA Approval of the ReZoom Multifocal Refractive Lens
SANTA ANA, Calif., March 28, 2005 Advanced Medical Optics, Inc. (AMO) (NYSE: AVO), a global leader in ophthalmic
surgical devices and eye care products, today added to its market-leading portfolio of refractive intraocular lenses
(IOL’s) with the announcement that the U.S. Food and Drug Administration (FDA) has approved the ReZoom® multifocal
refractive IOL for cataract patients.
The ReZoom® IOL is a new design and next generation acrylic three-piece multifocal IOL. The ReZoom® IOL Balanced
View Optics® distribute light over five optical zones for enhanced restoration of visual function, providing distance,
intermediate and near vision for reduced spectacle dependence. This allows the lens to match its performance characteristics
with the lifestyle demands of the patient.
“The ReZoom® multifocal lens adds to our portfolio of refractive IOL’s that already includes innovative technologies such
as the Verisyse® phakic IOL and the Tecnis® Multifocal lens, which is currently being evaluated in a clinical trial in
the U.S.,” said AMO President and CEO Jim Mazzo. “With our expansive portfolio of refractive IOL’s, AMO’s strategy is to lead
in building the burgeoning global refractive marketplace.”
Both the ReZoom® and Tecnis® Multifocal IOL’s have CE Mark approval in Europe for treatment of presbyopia.
Return to top
3/24/2005
FDA approves ReSTOR
Cataract and refractive surgeons will have a third intraocular lens option to improve patients’ near, distance, and
intermediate vision after last week’s approval of the ReSTOR (Alcon, Fort Worth, Texas) lens. The lens joins the
Array (Advanced Medical Optics, AMO, Santa Ana, Calif.) and Crystalens (eyeonics, Aliso Viejo, Calif.) as a Food and Drug
Administration (FDA)-approved IOL that aims to restore the three types of vision. The ReSTOR lens is approved for cataract
patients with and without presbyopia.
ReSTOR has an apodized diffractive optic design and refocuses light onto the retina
for images at various distances without having to move mechanically, company officials said. The end result is reduced
dependence on glasses for near, intermediate, and distance vision, they said. Patients that desire spectacle independence
after cataract surgery are ideal candidates for the lens, they said.
Clinical results showed 84% of patients that received
the ReSTOR lens in both eyes achieved distance visual acuity of 20/25 or better and near visual acuity of 20/32 or better
without correction by contacts or glasses, while only 23% of the conventional or monofocal control group achieved this level.
Return to top
3/18/2005
VISX CustomVue Mixed Astigmatism
Approved by the FDA
First U.S. Wavefront Procedure Approved for All Forms of Astigmatism
VISX announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to treat mixed astigmatism with the VISX CustomVue LASIK procedure.
The FDA approval allows for WaveScan diagnosis and CustomVue treatment of patients with mixed astigmatism. This approval is specifically for wavefront-guided LASIK for correction of mixed astigmatism from 1 to 5 D of cylinder.
The CustomVue procedure is now the only U.S. approved wavefront-guided laser treatment for myopic, hyperopic and mixed astigmatism.
Douglas Koch, M.D., of Baylor Vision at Baylor College of Medicine and principal investigator for the VISX mixed astigmatism clinical trial, stated, “The continued expansion of labeling for CustomVue allows me to treat more patients with what I believe is the very best procedure on the market today. Mixed astigmatism patients are especially challenging for ophthalmologists because their vision is often difficult to correct with glasses and contacts. The CustomVue treatment may give these patients the opportunity to see better than they could ever see with glasses or contacts.”
Return to top
3/11/2005
Jason Booth, producer of WISN’s “Weber & Dolan” has custom IntraLASIK at Hale Vision.
Jason had waited for the safety he felt available with the Intralase and the precision of the CustomVue wavefront treatment.
Return to top
3/3/2005
VISX Iris Registration Technology Approved by the FDA
First iris-based, automated method for aligning and registering wavefront correction adds more precision to the
CustomVue procedure
VISX, Incorporated today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Iris Registration technology, the first iris-based, automated, non-contact method of aligning and registering wavefront corrections for CustomVue treatment.
Iris Registration adjusts the laser ablation to compensate for any cyclotorsional movement and/or pupil migration that occurs when the patient goes from the upright to the supine position.
According to Julian Stevens, M.D., of Moorfields Eye Hospital in London, England, “Iris Registration adds another level of sophistication to Wavefront-guided laser vision correction treatments. By automatically adjusting the treatment for cyclotorsional rotation of the eye, Iris Registration provides more individualized adjustments that improve the precision of laser vision correction. This further enhances the quality of vision we achieve with the procedure.”
Return to top
12/15/2004
VISX CustomVue Hyperopia Procedure
Approved by the FDA
First U.S. Custom Wavefront LASIK Approval for
Farsightedness and Astigmatism
VISX announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to treat hyperopia and hyperopic astigmatism with the VISX CustomVue Hyperopic LASIK procedure.
The FDA approval allows for WaveScan® diagnosis and CustomVue™ treatment of patients with farsightedness and astigmatism. This approval is specifically for wavefront-guided LASIK for correction of hyperopia with or without astigmatism up to +3.00D MRSE, with cylinder up to +2.00D.
The CustomVue procedure is the first U.S. approved wavefront-guided laser treatment for hyperopia.
Colman Kraff, M.D., principal investigator with the VISX® multi-center clinical study, stated, “VISX’s new CustomVue Hyperopia procedure is a significant step forward in the treatment of farsightedness. The overall quality of vision with this new procedure is so superior that I plan to treat all of my qualified patients with CustomVue Hyperopia.”
A six-month evaluation of clinical study participants showed that more than four times as many people were very satisfied with their night vision after the VISX CustomVue hyperopia procedure, compared to their night vision before with glasses or contacts. TheVISX clinical study results also exceeded all of the FDA required parameters for safety and effectiveness.
Return to top
Sharing the Vision
Send a message to a friend with a direct link to this page.
